

| | | Category | Category | Status |
|--|--|----------|----------|--------|
| 1. ANAESTHETICS | | | | |
| 1.1 General anaesthetics and oxygen | | | | |
| 1.1.1 Inhalational medicines | | | | |
| halothane | Inhalation. | D | H | R |
| isoflurane | Inhalation. | D | H | R |
| nitrous oxide | Inhalation. | | | R |
| oxygen | Inhalation (medicinal gas). | | | R |
| 1.1.2 Injectable medicines | | | | |
| ketamine | Injection: 50 mg (as hydrochloride)/ml in 10-ml vial, 10mg/ml | D | H | R |
| propofol* | Injection: 10 mg/ml; 20 mg/ml. | D | H | R |
| 1.2 Local anaesthetics | | | | |
| ⊗ bupivacaine | Injection: 0.25%; 0.5% (hydrochloride) in vial. Injection for spinal anaesthesia: 0.5% (hydrochloride) in 4-ml ampoule to be mixed with 7.5% glucose solution. | D | H | R |
| ⊗ lidocaine | Injection: 1%; 2% (hydrochloride) in vial. Injection for spinal anaesthesia: 5% (hydrochloride) in 2-ml ampoule to be mixed with 7.5% glucose solution. Topical forms: 2% to 4% (hydrochloride). | D | H | R |
| lidocaine + epinephrine (adrenaline) | Dental cartridge: (2%-4%) (hydrochloride) + epinephrine 1:70 000- 1:80 000. Injection: 1%; 2% (hydrochloride or sulfate) + epinephrine 1:200 000 in vial. | D | H | R |
| <i>Complementary List</i> | | | | |
| Ephedrine | Injection: 30 mg (hydrochloride)/ml in 1-ml ampoule. (For use in spinal anaesthesia during delivery, to prevent hypotension). | D | H | R |

~ 1 ~



| 1.3 Preoperative medication and sedation for short-term procedures | | | | |
|--|--|---|---|---|
| Atropine | Injection: 1 mg (sulfate) in 1-ml ampoule. | A | H | R |
| © midazolam | Injection: 5mg/ml, 15mg/3ml Tablet: 2mg/ml | D | H | R |
| Morphine | Injection: 10 mg (sulfate or hydrochloride) in 1-ml ampoule. | D | H | R |
| 2. MEDICINES FOR PAIN AND PALLIATIVE CARE | | | | |
| 2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs) | | | | |
| acetylsalicylic acid | Suppository: 50 mg to 150 mg. Tablet: 100 mg , 325 mg, 500 mg | A | | R |
| ibuprofen a | Oral liquid: 100 mg/5 ml. Tablet: 200 mg; 400 mg; a Not in children less than 3 months. | A | | R |
| paracetamol a | Oral liquid: 125 mg/5 ml, 250 mg/5 ml Suppository: 125 mg, 250 mg Tablet: 500 mg. Inj: 1 g / 100 ml. a Not recommended for anti-inflammatory use due to lack of proven benefit to that effect. | A | | R |
| 2.2 Opioid analgesics | | | | |
| morphine a | Injection: 10 mg (morphine hydrochloride or morphine sulfate) in 1-ml ampoule | D | H | R |
| | Oral liquid: 10 mg (morphine hydrochloride or morphine sulfate)/5 ml. Tablet (slow release): 10 mg- 30 mg – 60 mg (morphine hydrochloride or morphine sulfate). Tablet (immediate release): 10 mg (morphine sulfate). a Alternatives limited to | D | | R |

~ 2 ~



| | | | | |
|--|---|----|---|---|
| | hydromorphone and oxycodone | | | |
| tramadol HCL | Injection: 100 mg / 2 ml | D | H | R |
| | Capsules: 50 mg Tablet: 100 mg | D | | R |
| 2.3 Medicines for other common symptoms in palliative care | | | | |
| amitriptyline | Tablet: 10 mg; 25 mg; | B | | R |
| dexamethasone | Injection: 4 mg/ml in 1-ml ampoule (as disodium phosphate salt). المراكز الصحية التي يتوفر فيها اخصائي باطني و اخصائي طب اسره | B | | R |
| | Solid oral dosage form: 0.5 mg, 4 mg Oral liquid: 0.5 mg/5 ml | A | | R |
| diazepam | Injection: 5 mg/ml. | A | H | R |
| | Tablet: 5 mg; 10 mg. | A | | R |
| fluoxetine a | Solid oral dosage form: 20 mg (as hydrochloride). a >8 years يصرف من قبل الاطباء في المراكز الصحية الحاصلين على موافقة الوزير لبرنامج سد الفجوة النفسية | B | | R |
| haloperidol | Injection: 5 mg in 1-ml ampoule. | C1 | H | R |
| | Oral liquid: 2 mg/ml. Solid oral dosage form: 5 mg, 10 mg | C1 | | |
| hyoscine butylbromide | Injection: 20 mg/ml. | A | H | R |
| lactulose [c] | Oral liquid: 3.1-3.7 g/5 ml. | A | | R |
| Loperamide | Solid oral dosage form: 2 mg. | D | | R |
| metoclopramide a | Injection: 5 mg (hydrochloride)/mL in 2-mL ampoule. | A | H | R |



| | | | | |
|---|--|---|---|-----------------|
| | Oral liquid: 5 mg/5 mL Solid oral form: 10 mg (hydrochloride) a use of metoclopramide is contraindicated in children younger than 1 year | A | | |
| Midazolam | Injection: 5 mg/ml, 15 mg/3 ml | D | H | R |
| | Oral liquid: 2mg/ml [c] | | | NR |
| ondansetron [c] a | Injection: 2 mg base/ml in 1-ml ampoule (as hydrochloride), 2 mg base/ml in 2-ml ampoule as hydrochloride) | D | H | R |
| | Solid oral dosage form: Eq 4 mg base; Eq 8 mg base. a >1 month. | | | |
| 3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS | | | | |
| Dexamethasone | Injection: 4 mg/ml in 1-ml ampoule (as disodium phosphate salt). | B | | R |
| epinephrine (adrenaline) | Injection: 1 mg (as hydrochloride or hydrogen tartrate) in 1-ml ampoule. | A | H | R |
| hydrocortisone | Powder for injection: 100 mg (as sodium succinate) in vial. | A | H | R |
| chlorpheniramine | Injection: 10 mg/ml | A | H | R |
| | Tablet: 4 mg Oral liquid: 2.5 mg/5 ml | A | | |
| ⊗ loratadine * | Oral liquid: 1 mg/ml. Tablet: 10 mg. *There may be a role for sedating antihistamines for limited indications (EMLC) | B | | R |
| ⊗ prednisolone | Oral liquid: 5 mg/ml [c]. Tablet: 5 mg; 25 mg. | B | | New application |
| 4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS | | | | |
| 4.1 Non-specific | | | | |
| charcoal, activated | powder | | | R |



| 4.2 Specific | | | | |
|--|--|---|---|----|
| acetylcysteine | Injection: 200 mg/ml in 10-ml ampoule. | D | H | R |
| | Oral liquid: 10% [c]; 20% [c]. | | | |
| atropine | Injection: 1 mg (sulfate) in 1-ml ampoule. | A | H | R |
| calcium gluconate | Injection: 100 mg/ml in 10-ml ampoule. | D | H | R |
| methylthioninium chloride (methylene blue) | Injection: 10 mg/ml in 10-ml ampoule. | D | H | R |
| naloxone | Injection: 0.02mg/ml, 0.4mg/ml | D | H | R |
| penicillamine | Solid oral dosage form: 250 mg. | D | | R |
| Complementary List | | | | |
| deferoxamine | Powder for injection: 500 mg (mesilate) in vial. | D | | R |
| dimercaprol | Injection in oil: 50 mg/ml in 2-ml ampoule. | D | H | IA |
| fomepizole | Injection: 5 mg/ml (sulfate) in 20-ml ampoule or 1 g/ml (base) in 1.5-ml ampoule. | | | NR |
| sodium calcium edetate | Injection: 200 mg/ml in 5-ml ampoule. | | | NR |
| succimer | Solid oral dosage form: 100 mg. | | | NR |
| 5. ANTICONVULSANTS/ANTIEPILEPTICS | | | | |
| carbamazepine | Oral liquid: 100 mg/5 ml. Tablet (scored): 200 mg; 400 mg Tablet controlled release: 200 mg, 400 mg | A | | R |
| clonazepam | Oral drops: 2.5 mg/ml Tablet: 0.5 mg, 2 mg | B | | R |
| magnesium sulfate* | Injection: 500 mg/ml in 2-ml ampoule; 500 mg/ml in 10-ml ampoule. * For use in eclampsia and severe pre-eclampsia and not for other convulsant disorders. | D | H | NR |
| Phenobarbital | Injection: 200 mg/ml (sodium), 40 mg/ml | D | H | R |
| | Tablet: 15 mg, 30 mg, 60 mg. | A | | |

~ 5 ~



| | | | | |
|---|--|----|---|---------|
| Phenytoin | Injection: 50 mg/ml in 5-ml vial (sodium salt). | B | H | R |
| | Oral liquid: 30 mg/5 ml.* Solid oral dosage form: 100 mg(sodium salt). | B | | NR R |
| valproic acid (sodium valproate) | Oral liquid: 200 mg/1 ml, 300 mg/1 ml | B | | R |
| | Tablet (enteric-coated): 150 mg-500 mg (sodium valproate). | C1 | | |
| <i>Complementary List</i> | | | | |
| ethosuximide | Capsule: 250 mg. Oral liquid: 250 mg/5 ml. | | | NR |
| 6. ANTI-INFECTIVE MEDICINES | | | | |
| 6.1 Anthelmintics | | | | |
| 6.1.1 Intestinal anthelmintics | | | | |
| Albendazole | Tablet: 200 mg. | | | R |
| mebendazole | Tablet: 100 mg; 500 mg. Oral liquid: 20 mg/ml | A | | R |
| praziquantel | Tablet: 600 mg | C | | R |
| 6.1.2 Antifilarials | | | | |
| Albendazole | Tablet: 200 mg. | | | R |
| 6.1.3 Antischistosomes and other antitrematode medicines | | | | |
| praziquantel | Tablet: 600 mg | C | | R |
| 6.2 Antibacterials | | | | |
| 6.2.1 Beta Lactam medicines | | | | |
| Amoxicillin | Powder for oral liquid: 125 mg (as trihydrate)/5 ml; 250 mg (as trihydrate)/5 ml [c]. Solid oral dosage form: 250 mg; 500 mg (as trihydrate). | A | | R |
| amoxicillin + clavulanic acid | Oral liquid: 125 mg amoxicillin + 31.25 mg clavulanic acid/5 ml; 250 mg amoxicillin +62.5 mg clavulanic acid/5 ml AND 400 mg amoxicillin + 57 mg clavulanic acid/5 ml [c]. Tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); amoxicillin | A | | R |

~ 6 ~

A مراكز اولية:
B مراكز شاملة:
C مراكز متخصصة:
C1 عيادات نفسية:
D مستشفيات:



| | | | | |
|--|---|---|---|----|
| | 875 mg + 125 mg clavulanic acid. Injection: amoxicillin 1 g, clavulanic Acid 0.2 g; amoxicillin 500 mg, potassium Clavulanate 100 mg | | | |
| Ampicillin | Powder for injection: 250 mg;500 mg; 1 g (as sodium salt) in vial. | A | H | R |
| benzathine benzylpenicillin | Powder for injection: 2,400,000 IU | A | H | R |
| procaine penzylpenicillin benzathine benzylpenicillin benzylpenicillin | Powder for injection: 300000 IU: 600000 IU :300000 IU | | | R |
| benzylpenicillin | Powder for injection: 600 mg (= 1 million IU) | D | H | R |
| cefalexin [c] | Powder for reconstitution with water: 125 mg/5 ml;250 mg/5 ml (anhydrous). Solid oral dosage form: 250 mg (as monohydrate); 500 mg (as monohydrate) | A | | R |
| ⊙ cefazolin* a | Powder for injection: 1 g (as sodium salt) in vial. * For surgical prophylaxis. a >1 month. | D | H | R |
| cefixime | Capsule: 200 mg (as trihydrate) 400 mg (as trihydrate). Oral liquid: 100mg/5 ml | B | | R |
| ceftriaxone* a | Powder for injection: 250 mg; 500 mg; 1 g (as sodium salt) in vial. * Do not administer with calcium and avoid in infants with hyperbilirubinemia. a >41 weeks corrected gestational age. | D | H | R |
| flucloxacillin | Capsules: 250 mg, 500 mg Powder for oral liquid: 125 mg/5 ml | A | | R |
| phenoxymethylpenicillin | Powder for oral liquid: 250 mg (as potassium salt)/5 ml. Tablet: 250 mg (as potassium salt). | A | | R |
| procaine benzylpenicillin* | Powder for injection: PROCAINE | A | H | NR |

~ 7 ~



| | | | | |
|-----------------------------------|--|----------|----------|-----------|
| | BENZYL PENICILLIN INJ 400,000 IU * Procaine benzylpenicillin is not recommended as first-line treatment for neonatal sepsis except in settings with high neonatal mortality, when given by trained health workers in cases where hospital care is not achievable. | | | |
| <i>Complementary List</i> | | | | |
| cefotaxime* [c] | Powder for injection: 500 mg per vial (as sodium salt). * 3rd generation cephalosporin of choice for use in hospitalized neonates. | D | H | R |
| colistimethate sodium | Powder for injection: 2 million | D | H | NR |
| imipenem* + cilastatin* | Powder for injection: 500 mg (as monohydrate) + 500 mg (as sodium salt) in vial. * Only listed for the treatment of life-threatening hospital based infection due to suspected or proven multidrug resistant infection. Meropenem is indicated for the treatment of meningitis and is licensed for use in children over the age of 3 months. Powder for injection: PIPERACILLIN+TAZOBACTAM 4.5 gm * Only listed for the treatment of life-threatening hospital based infection due to suspected or proven multidrug resistant infection. | D | H | NR |
| 6.2.2 Other antibacterials | | | | |
| azithromycin | Capsule: 250 mg; 500 mg (anhydrous). Oral liquid: 200 mg/5 ml. | A | | R |
| © ciprofloxacin* | Solution for IV infusion: 2 mg/ml (as hyclate) [c]. | A | | R |

~ 8 ~



| | | | | |
|------------------------------------|---|---|---|----|
| | Tablet: 250 mg (as hydrochloride), 500 mg (as hydrochloride), 750 mg (as hydrochloride) * Square box applies to adults only. | | | |
| clarithromycin | Solid oral dosage form: 250 mg, 500 mg Oral liquid: 125 mg/ 5 ml, 250 mg/5 ml | A | | R |
| doxycycline a | Solid oral dosage form: 100 mg (as hydrate). a Use in children <8 years only for life-threatening infections when no alternative exists. | A | | R |
| ⊙ erythromycin | Powder for oral liquid: 125 mg/5 ml (as stearate or estolate or ethyl succinate). Solid oral dosage form: 250 mg (as stearate or estolate or ethyl succinate). | A | | R |
| ⊙ gentamicin | Injection: 40 mg (as sulfate)/ml in 2- ml vial. | B | H | R |
| ⊙ metronidazole | Injection: 500 mg in 100-ml vial. | D | H | R |
| | Oral liquid: 125 mg (as benzoate)/5 ml. Suppository: 500 mg; Tablet: 250 mg - 500 mg. | A | | R |
| nitrofurantoin | Oral liquid: 25 mg/5 ml [c]. Tablet: 100 mg. | B | | IA |
| sulfamethoxazole + trimethoprim | Injection: 80 mg, 400 mg/ml in 5 ml ampoule. Oral liquid: 200 mg + 40 mg/5 ml. Tablet DS/FORTE: 800 mg +160 mg. Tablet: 400 mg + 80 mg | B | | R |
| <i>Complementary List</i> | | | | |
| clindamycin | Capsule: 150 mg (as hydrochloride), 300 mg (as hydrochloride) Injection: 300 mg/ 2 ml, 600 mg/ 4 ml (as phosphate)/ml. Oral liquid: 75 mg/5 ml (as | A | | R |

~ 9 ~



| | | | | |
|---|---|--------|---|----|
| | palmitate) [c]. Lincomycin as an alternative when clindamycin is not available. | | | |
| vancomycin | Powder for injection: 500 mg (as hydrochloride) in vial. TEICOPLANIN when vancomycin cannot be used. | D | H | R |
| 6.2.3 Antileprosy medicines | | | | |
| Medicines used in the treatment of leprosy should never be used except in combination. Combination therapy is essential to prevent the emergence of drug resistance. Colour coded blister packs (MDT blister packs) containing standard two medicine (paucibacillary leprosy) or three medicine (multibacillary leprosy) combinations for adult and childhood leprosy should be used. MDT blister packs can be supplied free of charge through WHO. | | | | |
| clofazimine | Capsule: 50 mg; 100 mg. | C | | NR |
| dapsone | Tablet: 25 mg; 50 mg; 100 mg. | B | | NR |
| rifampicin | Solid oral dosage form: 150 mg; 300 mg. | C | | R |
| 6.2.4 Antituberculosis medicines | | | | |
| WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and pediatric dosage forms of assured pharmaceutical quality. | | | | |
| ethambutol | Oral liquid: 25 mg/ml [c]. Tablet: 400 mg (hydrochloride). | C | | NR |
| ethambutol + isoniazid | Tablet: 400 mg + 150 mg. | C | | NR |
| ethambutol + isoniazid + pyrazinamide + rifampicin | Tablet: 275 mg + 75 mg + 400 mg + 150 mg. | C | | NR |
| ethambutol + isoniazid + rifampicin | Tablet: 275 mg + 75 mg + 150 mg. | C | | NR |
| isoniazid | Oral liquid: 50 mg/5 ml [c]. Tablet: 100 mg to 300 mg. Tablet (scored): 50 mg. | C | | NR |
| isoniazid + pyrazinamide + rifampicin | Tablet: 75 mg + 400 mg + 150 mg. 150 mg + 500 mg + 150 mg (For intermittent use) | C C | | NR |

~ 10 ~



| | | | | |
|--|---|---|---|---------|
| | three times weekly). | | | |
| isoniazid + rifampicin | Tablet: 75 mg + 150 mg; 150 mg + 300 mg. 60 mg + 60 mg (For intermittent use three times weekly). 150 mg + 150 mg (For intermittent use three times weekly). | C | | NR |
| pyrazinamide | Oral liquid: 30 mg/ml [c]. Tablet: 400 mg. Tablet (dispersible): 150 mg. Tablet (scored): 150 mg. | C | | NR |
| rifabutin | Capsule: 150 mg.* * For use only in patients with HIV receiving protease inhibitors. | C | | R |
| rifampicin | Oral liquid: 20 mg/ml [c]. Solid oral dosage form: 150 mg; 300 mg. | C | | NR R |
| streptomycin | Powder for injection: 1 g (as sulfate) in vial. | C | | NR |
| <i>Complementary List</i> | | | | |
| Reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centers adhering to WHO standards for TB control. | | | | |
| amikacin | Powder for injection: 100 mg; 250 mg; 500 mg; (as sulfate) in vial. | D | H | R |
| kanamycin | Powder for injection: 1 g (as sulfate) in vial | D | H | NR |
| levofloxacin* | Tablet: 250mg; 500 mg; * Ofloxacin and moxifloxacin may be alternatives based on availability and programme considerations. | B | | R |
| streptomycin [c] | Powder for injection: 1 g (as sulfate) in vial. | C | H | NR |
| 6.3 Antifungal medicines | | | | |



| | | | | |
|--|--|---|---|---------|
| amphotericin B | Powder for injection: 50 mg in vial (as sodium deoxycholate or liposomal complex). | D | H | R |
| clotrimazole | Vaginal cream: 1%; 10%. Vaginal tablet: 100 mg; 500 mg. | A | | R |
| © fluconazole | Injection: 2 mg/ml in vial. | D | H | R |
| | Oral liquid: 50 mg/5 ml. Capsule: 50 mg. | B | | NR R |
| griseofulvin | Oral liquid: 125 mg/5 ml [c]. Solid oral dosage form: 250 mg, 500 mg | A | | NR R |
| nystatin | Oral liquid: 100 000 IU/ml [c]. | A | | R |
| <i>Complementary List</i> | | | | |
| potassium iodide | Saturated solution | A | | R |
| 6.4 Antiviral medicines | | | | |
| 6.4.1 Antiherpes medicines | | | | |
| © acyclovir | Powder for injection: 250 mg (as sodium salt) in vial. | D | H | R |
| | Tablet: 200 mg. Cream: 5mg/g Oral liquid: 200 mg/5 ml [c]. | B | | |
| 6.4.2 Antiretrovirals | | | | |
| Based on current evidence and experience of use, medicines in the following three classes of antiretrovirals are included as essential medicines for treatment and prevention of HIV (prevention of mother-to-child transmission and post-exposure prophylaxis).WHO emphasizes the importance of using these products in accordance with global and national guidelines. WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations,including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality. Scored tablets can be used in children and therefore can be considered for inclusion in the listing of tablets,provided adequate quality products are available. | | | | |
| 6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors | | | | |

~ 12 ~



| | | | | |
|---|--|------------|---|----|
| lamivudine | Tablet: 150 mg | D | | R |
| zidovudine (ZDV or AZT) | Capsule: 100 mg; 250 mg. Tablet: 300 mg. Oral liquid: 50 mg/5 ml. Solution for IV infusion injection: 10 mg/ml in 20-ml vial. | C D | H | R |
| 6.4.2.2 Non-nucleoside reverse transcriptase inhibitors | | | | |
| 6.4.2.3 Protease inhibitors | | | | |
| FIXED-DOSE COMBINATIONS | | | | |
| lamivudine + zidovudine | Tablets: 150 mg + 300 mg | C | | R |
| efavirenz + emtricitabine* + tenofovir | Tablets: 600 mg + 200 mg + 300 mg | C | | NR |
| 6.4.3 Other antivirals | | | | |
| oseltamivir* | Capsule: 75 mg (as phosphate). Oral powder: 12 mg/ml. * potentially severe or complicated illness due to confirmed or suspected influenza virus infection in accordance with WHO treatment guidelines. | B | | R |
| Zanamivir | Diskhaler: 5mg | C | | R |
| ribavirin* | Injection for intravenous administration: 800 mg and 1 g in 10-ml phosphate buffer solution. Solid oral dosage form: 200 mg; * For the treatment of viral haemorrhagic fevers and in combination with pegylated interferons for the treatment of Hepatitis C | D | | R |
| <i>Complementary List</i> | | | | |
| pegylated interferon alpha (2a or 2b) * | Vial or prefilled syringe: 180 micrograms (peginterferon alfa-2a); 80 micrograms, 100 micrograms (peginterferon alfa-2b). * To be used in combination with ribavirin. | D | | R |

~ 13 ~



| 6.5 Antiprotozoal medicines | | | | |
|---|--|------------|---|----|
| 6.5.1 Antiamoebic and anti giardiasis medicines | | | | |
| diloxanide a | Tablet: 500 mg (furoate). a >25 kg. | A | | NR |
| © metronidazole | Injection: 500 mg in 100-ml vial. Oral liquid: 125 mg (as benzoate)/5 ml. Tablet: 200 mg to 500 mg. | D A | H | R |
| 6.5.2 Antileishmaniasis medicines | | | | |
| amphotericin B | Powder for injection: 50 mg in vial (as sodium deoxycholate or liposomal complex). | D | H | R |
| sodium stibogluconate or meglumine antimoniate | Injection: 100 mg/ml, 1 vial = 30 ml or 30%, equivalent to approximately 8.1% antimony (pentavalent) in 5-ml ampoule. | D | H | R |
| 6.5.3 Antimalarial medicines | | | | |
| 6.5.3.1 For curative treatment | | | | |
| Medicines for the treatment of P. falciparum malaria cases should be used in combination. The list currently recommends combinations according to treatment guidelines. WHO recognizes that not all of the FDCs in the WHO treatment guidelines exist, and encourages their development and rigorous testing. WHO also encourages development and testing of rectal dosage formulations. | | | | |
| chloroquine* | Oral liquid: 75 mg (as phosphate or sulfate)/5 ml. Tablet: 150 mg (as phosphate or sulfate). * For use only for the treatment of P. vivax infection. | C | | R |
| doxycycline | Capsule: 100 mg (as hydrochloride or hyclate). | A | | R |
| mefloquine* | Tablet: 250 mg (as hydrochloride). * To be used in combination with artesunate 50 mg. | C | | R |
| primaquine* | Tablet: 15 mg (as diphosphate). | C | | NR |

~ 14 ~



| | | | | |
|--|---|--------|---|----|
| | * Only for use to achieve radical cure of <i>P.vivax</i> and <i>P.ovale</i> infections, given for 14 days. | | | |
| quinine* | Injection: 600 mg quinine hydrochloride/ml in 2-ml ampoule. Tablet: 300 mg (quinine sulfate) or 300 mg (quinine bisulfate). * For use only in the management of severe malaria, and should be used in combination with doxycycline. | C | | R |
| 6.5.3.2 For prophylaxis | | | | |
| hydroxychloroquine* | Tablet: 200 mg (as phosphate or sulfate). * For use only in central American regions, for use for <i>P.vivax</i> . | C | | R |
| doxycycline a | Solid oral dosage form: 100 mg (as hydrochloride or hyclate). a >8 years. | A | | R |
| mefloquine a | Tablet: 250 mg (as hydrochloride). a >5 kg or >3 months. | C | | R |
| 6.5.4 Antipneumocystosis and antitoxoplasmosis medicines | | | | |
| pyrimethamine | Tablet: 25 mg. | C | | NR |
| sulfadiazine | Tablet: 500 mg. | C | | NR |
| sulfamethoxazole + trimethoprim | Injection: 80 mg, 400 mg/ml in 5 ml ampoule. Oral liquid: 200 mg + 40 mg/5 ml. Tablet DS/FORTE: 800 mg +160 mg. Tablet: 400 mg + 80 mg | D C | H | R |
| 7. ANTIMIGRAINE MEDICINES | | | | |
| 7.1 For treatment of acute attack | | | | |
| acetylsalicylic acid | Tablet: 300 mg to 500 mg. | A | | R |
| ibuprofen [c] | Tablet: 200 mg; 400 mg. | A | | R |
| paracetamol | Oral liquid: 125 mg/5 ml [c]. Tablet: 500 mg. | A | | R |
| 7.2 For prophylaxis | | | | |

~ 15 ~



| | | | | |
|---|--|--------|---|---|
| © propranolol | Tablet: 20 mg; 40 mg (hydrochloride). | A | | R |
| 8. ANTINEOPLASTIC AND IMMUNOSUPPRESSIVES | | | | |
| 8.1 Immunosuppressive medicines | | | | |
| <i>Complementary List</i> | | | | |
| azathioprine | Tablet (scored): 50 mg. | D | | R |
| ciclosporin | Capsule: 25 mg, 50mg, 100mg Solution for infusion: 50mg/ml Oral solution: 100mg/ml * Tacrolimus may be alternatives based on availability and programme considerations | D | H | R |
| 8.2 Cytotoxic and adjuvant medicines | | | | |
| <i>Complementary List</i> | | | | |
| allopurinol [c] | Tablet: 100 mg; 300 mg. | A | | R |
| asparaginase | Powder for injection: 10 000 IU in vial. | D | H | |
| Bleomycin | Powder for injection: 15 mg (as sulfate) in vial. | D | H | R |
| calcium folinate | Injection: 10 mg/ml in 5-ml ampoule. Tablet: 15 mg. | D | H | R |
| © carboplatin | Injection: 150 mg/15 ml; 450 mg/45 ml | D | H | R |
| chlorambucil | Tablet: 2 mg. | D | | R |
| cyclophosphamide | Powder for injection: 500 mg in vial, 1000mg in vial. Tablet: 50 mg. | D D | H | R |
| cytarabine | Powder for injection: 100 mg in vial; 500mg in vial; 1000mg in vial | D | H | R |
| dacarbazine | Powder for injection: 100 mg in vial. | D | H | R |
| dactinomycin | Powder for injection: 500 micrograms in vial. | D | H | R |
| daunorubicin | Powder for injection: 50 mg (hydrochloride) in vial. | D | H | R |
| docetaxel | Injection: 20mg/0.5ml; 80mg/2ml | D | H | R |
| doxorubicin | Powder for injection: 10mg, 50mg (hydrochloride) in vial. | D | H | R |
| etoposide | Capsule: 100 mg. Injection: 20 mg/ml in 5-ml ampoule. | D D | H | R |
| fluorouracil | Injection: 50 mg/ml in 5-ml ampoule, 500 mg/10ml , 1000 mg/20ml. | D | H | R |
| hydroxycarbamide | Solid oral dosage form: 200 mg; 250 mg; 300 mg; 400mg; 500 mg; 1 g. | D | | R |
| ifosfamide | Powder for injection: 1 g vial; 2 g vial. | D | H | R |



| | | | | |
|-------------------------------|---|--------|---|----|
| mercaptopurine | Tablet: 50mg | D | | R |
| mesna | Injection: 100 mg/ml in 4-ml and 10-ml ampoules. | D | H | R |
| methotrexate | Powder for injection: 50 mg (as sodium salt) in vial, 500mg in vial, 1000mg in vial, 5000mg in vial Tablet: 2.5 mg (as sodium salt). | D | H | R |
| paclitaxel | Powder for injection: 6mg/ml | D | H | R |
| procarbazine | Capsule: 50 mg (as hydrochloride). | D | | NR |
| thioguanine [c] | Solid oral dosage form: 40 mg. | D | | NR |
| vinblastine | Powder for injection: 10 mg (sulfate) in vial. | D | H | R |
| vincristine | Powder for injection: 1mg/1 ml (sulfate) in vial | D | H | R |
| busuflan | Tablet: 2 mg | D | | NR |
| temozolamide | Capsules: 100mg, 250mg | D | | NR |
| danuorubacin | Injection: 20mg | D | H | NR |
| idarubicin | Injection: 5mg, 10mg | D | H | R |
| melphalan | Tablet: 2mg Injection: 50mg | D D | H | R |
| dactinomycin | Injection: 0.5mg vial | D | H | R |
| cladribine | Injection: 10mg | D | H | R |
| fludarabine | Injection: 50mg | D | H | R |
| gemcitabine | Injection: 200mg, 1000mg | D | H | R |
| hydroxyurea | Cap: 500mg | D | | R |
| imatinib | Tab: 100mg, 400mg | D | | R |
| cisplatin | Injection: 0.5mg/ml, 1mg/ml | D | H | R |
| oxaliplatin | Injection: 5mg/ml | D | H | R |
| irinotecan | Injection: 20mg/ml | D | H | R |
| thalidomide | Tablet: 50mg | D | | R |
| filgrastim | Injection: 30 mu/0.5ml, 48 mu/0.5ml | D | H | R |
| Mycophenolate | Tablets: 360mg, 500mg | D | | R |
| 8.3 Hormones and antihormones | | | | |
| <i>Complementary List</i> | | | | |
| Dexamethasone | Injection: 4 mg/ml in 1-ml ampoule (as disodium phosphate salt). Solid oral dosage form: 0.5 mg, 4 mg Oral liquid: 0.5 mg/5 ml | B A | | R |
| Hydrocortisone | Powder for injection: 100mg (as sodium succinate) in vial. | A | H | R |

~ 17 ~



| | | | | |
|--|--|----|---|---|
| | Tablet: 20 mg | D | | |
| methylprednisolone [c] | Injection: Injection: 500 mg/8ml. | D | H | R |
| ⊙ prednisolone | Tablet: 5mg | B | | R |
| Tamoxifen | Tablet: 20mg (as citrate) | D | | R |
| 9. ANTIPARKINSONISM MEDICINES | | | | |
| ⊙ biperiden | Tablet: 4 mg يصرف فقط من قبل اخصائي نفسية | C1 | | R |
| levodopa + ⊙ carbidopa | Tablet: 100mg+25mg; | A | | R |
| 10. MEDICINES AFFECTING THE BLOOD | | | | |
| 10.1 Antianaemia medicines | | | | |
| ferrous salt | Oral liquid: equivalent to 25 mg iron (as sulfate)/ml. Tablet: equivalent to 15mg- 30mg iron. | A | | R |
| ferrous salt + folic acid | Tablet: equivalent to (30mg – 60mg) iron + 400 micrograms folic acid (Nutritional supplement for use during pregnancy). | A | | R |
| folic acid | Tablet: 1 mg; 5 mg. | A | | R |
| hydroxocobalamin | Injection: 1 mg (as acetate, hydrochloride or as sulfate) in 1-ml ampoule. | A | | R |
| 10.1.1 DRUGS USED IN HYPOPLASTIC, HAEMOLYTICS, AND RENAL ANAEMIAS | | | | |
| erythropoietin alpha & Beta | Injection: 2000-40,000 IU | D | H | R |
| 10.2 Medicines affecting coagulation | | | | |
| heparin sodium | Injection: 5000 IU/ml; 10 000 IU/ml in 1-ml ampoule. | D | H | R |
| phytomenadione | Injection: 2mg [c]; 10 mg/ml in 5-ml ampoule. | D | | R |
| protamine sulfate | Injection: 10 mg/ml in 5-ml ampoule. | D | H | |
| tranexamic acid | Injection: 100 mg/ml in 10-ml ampoule. | D | H | R |
| ⊙ warfarin | Tablet: 3mg; 5 mg (sodium salt). | | | R |
| <i>Complementary List [c]</i> | | | | |
| heparin sodium | Injection: 1000 IU/ml; 5000 IU/ml in 1-ml ampoule. *LMWH may be an alternative depending on cost and availability | D | H | R |
| protamine sulfate | Injection: 10 mg/ml in 5-ml ampoule. | D | H | |
| ⊙ warfarin | Tablet: 3mg; 5 mg (sodium salt). | B | | R |



| 10.3 Other medicines for haemoglobinopathies | | | | |
|---|--|---|---|---|
| <i>Complementary List</i> | | | | |
| deferroxamine* | Powder for injection: 500 mg (mesilate) in vial. * Deferasirox oral form may be an alternative, depending on cost and availability. | D | | R |
| hydroxycarbamide | Solid oral dosage form: 200 mg; 500 mg; 1 g. | D | | R |
| 11. BLOOD PRODUCTS AND PLASMA SUBSTITUTES OF HUMAN ORIGIN | | | | |
| 11.1 Blood and blood components | | | | |
| fresh frozen plasma | | D | H | |
| platelet concentrates | | D | H | |
| red blood cells | | D | H | |
| whole blood | | D | H | |
| 11.2 Plasma-derived medicines | | | | |
| All human plasma derived medicines should comply with the MOH Requirements. | | | | |
| 11.2.1 Human immunoglobulins | | | | |
| <i>Complementary List</i> | | | | |
| human normal immunoglobulin | Intramuscular administration: 16% protein solution.* Intravenous administration: 5%; 10% protein solution.** Subcutaneous administration: 15%; 16% protein solution.* * Indicated for primary immune deficiency. **Indicated for primary immune deficiency and Kawasaki disease. | D | H | R |
| 11.2.2 Blood coagulation factors | | | | |
| <i>Complementary List</i> | | | | |
| <input type="checkbox"/> coagulation factor VIII | Powder for injection: 500 IU/vial. | D | H | R |
| <input type="checkbox"/> coagulation factor IX | Powder for injection: 500 IU/vial, 1000 IU/vial. | D | H | R |
| 12. CARDIOVASCULAR MEDICINES | | | | |
| 12.1 Antianginal medicines | | | | |
| <input type="checkbox"/> bisoprolol* | Tablet: 5mg and 10mg . | A | | R |

~ 19 ~



| | | | | |
|--|---|--------|---|----|
| | * □ includes metoprolol and carvedilol as alternatives | | | |
| glyceryl nitrate | Injection: 10mg Tablet (sublingual) : 500 microgram | D | H | R |
| □ isosorbide dinitrate | Tablet : (sublingual) 5mg and 40mg | A | | R |
| verapamil | Tablet: 80mg and 240mg | B | | R |
| 12.2 Antiarrhythmic medicines | | | | |
| □ bisoprolol * | Tablet: 2.5mg and 5 mg and 10mg . * □ includes metoprolol and carvedilol as alternatives | A | | R |
| digoxin | Oral liquid: 50 micrograms/ml. Tablet: 62.5 micrograms; 250 micrograms | A | | R |
| epinephrine | Injection: 100 micrograms/ml (as acid tartrate or hydrochloride) in 10-ml ampoule. | A | H | R |
| norepinephrine | 2mg /ml in 4ml ampoule | A | H | R |
| verapamil | Injection: 2.5 mg (hydrochloride)/ml in 2-ml ampoule. Tablet: 80 mg and 240mg (hydrochloride). | B B | H | R |
| adenosine | Injection: 6mg | D | H | R |
| <i>Complementary List</i> | | | | |
| Amiodarone | Injection: 50 mg/ml in 3-ml ampoule (hydrochloride). Tablet (HCl): 200 mg (hydrochloride). | D A | H | R |
| 12.3 Antihypertensive medicines | | | | |
| □ amlodipine | Tablet: 5 mg (as maleate, mesylate or besylate). | A | | R |
| □ bisoprolol * | Tablet: 5 mg and 10mg . * □ includes metoprolol and carvedilol as alternatives | A | | R |
| enalapril* | Tablet: 5 mg and 10mg and 20mg (as hydrogen maleate). *include Valsartan as alternative | A | | R |
| hydralazine | Powder for injection: 20 mg (hydrochloride) in ampoule. Tablet: 25 mg and 50 mg | D | H | NR |

~ 20 ~



| | | | | |
|--|--|--------|---|----|
| | (hydrochloride). * Hydralazine is listed for use in the acute management of severe pregnancy-induced hypertension only. Its use in the treatment of essential hypertension is not recommended in view of the availability of more evidence of efficacy and safety of other medicines. | A | | |
| <input type="checkbox"/> hydrochlorothiazide | Oral liquid: 50 mg/5 ml. Solid oral dosage form: 25 mg. | A | | NR |
| methyldopa* | Tablet: 250 mg. * Methyldopa is listed for use in the management of pregnancy-induced hypertension only. Its use in the treatment of essential hypertension is not recommended in view of the availability of more evidence of efficacy and safety of other medicines. | A | | R |
| <i>Complementary List</i> | | | | |
| sodium nitroprusside | Powder for infusion: 50 mg in ampoule. | D | H | NR |
| 12.3.1 Enotropic sympathomimetics | | | | |
| Dobutamine | Injection:250mg | D | H | R |
| 12.4 Medicines used in heart failure | | | | |
| <input type="checkbox"/> bisoprolol * | Tablet: 5 mg and 10mg . * <input type="checkbox"/> includes metoprolol and carvedilol as alternatives | A | | R |
| digoxin | Oral liquid: 50 micrograms/ml. Tablet: 62.5 micrograms; 250 micrograms | A | | R |
| <input type="checkbox"/> furosemide | Injection: 10 mg/ml in 2-ml ampoule. Oral liquid: 20 mg/5 ml [c]. Tablet: 40 mg. | A A | H | R |
| <input type="checkbox"/> hydrochlorothiazide | Oral liquid: 50 mg/5 ml. Solid oral dosage form: 25 mg. | A | | NR |
| spironolactone | Tablet: 25 mg. | A | | R |
| <i>Complementary List</i> | | | | |
| Dopamine | | | | R |
| 12.5 Antithrombotic medicines | | | | |
| acetylsalicylic acid | Tablet: 100 mg. | A | | R |
| clopedogril | Tablet: 75 mg. | D | | R |
| <i>Complementary List</i> | | | | |

~ 21 ~

A مراكز اولية:
B مراكز شاملة:
C مراكز متخصصة:
عيادات نفسية: C1
مستشفيات: D

الرمز H يعني استخدامه داخل المستشفى

ادوية تم اضافتها



| | | | | |
|--|--|--------------------------------|---|----|
| streptokinase* | Powder for injection: 1.5 and 250.000million IU in vial. *Altiplase 50mg injection depending on availability and cost | D | H | R |
| 12.6 Lipid-lowering agents | | | | |
| <input type="checkbox"/> simvastatin* | Tablet: 20 mg. * For use in high-risk patients. | A | | R |
| gemfibrozil | Tablet: 600mg | A | | R |
| 13. DERMATOLOGICAL MEDICINES (topical) | | | | |
| 13.1 Antifungal medicines | | | | |
| <input type="checkbox"/> miconazole | Lotion: 2% (nitrate) | A | | R |
| terbinafine | Cream: 1% or Ointment: 1% terbinafine hydrochloride. | B | | R |
| 13.2 Anti-infective medicines | | | | |
| mupirocin | Cream (as mupirocin calcium): 2%. Ointment: 2%. | A | | R |
| potassium permanganate | Aqueous solution: 1:10 000. | D | | R |
| silver sulfadiazine a | Cream: 1%. a >2 months. | D | | R |
| fusidic Acid | Cream 1%, Ointment 2% | A | | R |
| fusidic Acid+ hydrocortisone acetate | Cream 1%, 2% | A مراكز بها اخصائي جلدية | | R |
| 13.3 Anti-inflammatory and antipruritic medicines | | | | |
| <input type="checkbox"/> betamethasone a | Cream or ointment: 0.1% (as valerate).a Hydrocortisone preferred in neonates. | A | | R |
| <input type="checkbox"/> calamine + zinc oxide | Lotion | A | | NR |
| <input type="checkbox"/> hydrocortisone | Cream or ointment: 1% (acetate). | A | | R |
| 13.4 Medicines affecting skin differentiation and proliferation | | | | |
| benzoyl peroxide | Gel: 5% | A | | R |
| salicylic acid | Solution, cream | A | | R |
| 13.5 Scabicides and pediculicides | | | | |
| <input type="checkbox"/> benzyl benzoate a | Lotion: 25%. a >2 years. | A | | R |
| crotamiton | Cream or lotion: 10% | A | | R |
| permethrin | Cream: 5%. Lotion: 1%. | A | | R |
| 14. DIAGNOSTIC AGENTS | | | | |
| 14.1 Ophthalmic medicines | | | | |

~ 22 ~



| | | | | |
|---|--|--------|---|----|
| fluorescein | Eye drops: 1% (sodium salt). | D | H | R |
| <input type="checkbox"/> tropicamide | Eye drops: 0.5%. | D | H | R |
| 14.2 Radiocontrast media | | | | |
| barium sulfate | Aqueous suspension, Enema, powder | D | H | R |
| <input type="checkbox"/> iohexol | Injection: 180mg-755mg/ml | D | H | R |
| <i>Complementary List</i> | | | | |
| barium sulfate [c] | Aqueous suspension, Enema, powder | D | H | R |
| 15. DISINFECTANTS AND ANTISEPTICS | | | | |
| 15.1 Antiseptics | | | | |
| <input type="checkbox"/> chlorhexidine | Solution: 5% (digluconate). | A | | R |
| <input type="checkbox"/> ethanol | Solution: 70% (denatured). | A | | R |
| <input type="checkbox"/> polyvidone iodine | Solution: 10% (equivalent to 1% available iodine). | A | | - |
| 15.2 Disinfectants | | | | |
| <input type="checkbox"/> chlorine base compound | Powder: (0.1% available chlorine) for solution. | A | | - |
| <input type="checkbox"/> chloroxylenol | Solution: 4.8%. | A | | |
| glutaral | Solution: 2%. | A | | R |
| 16. DIURETICS | | | | |
| ⊗ furosemide | Injection: 10 mg/ml in 2-ml ampoule. Tablet: 40 mg. | A A | H | R |
| ⊗ hydrochlorothiazide | Solid oral dosage form: 25 mg. | A | | - |
| Spirolactone | Tablet: 25 mg. | A | | R |
| <i>Complementary List</i> | | | | |
| ⊗ hydrochlorothiazide | Tablet: 25 mg. | A | | NR |
| spironolactone | Tablet: 25 mg. | A | | R |
| 17. GASTROINTESTINAL MEDICINES | | | | |
| <i>Complementary List [c]</i> | | | | |
| ⊗ pancreatic enzymes | PANCREATIN (AMYLASE +LIPASE +PROTEASE) CAPS OR TABS | D | | R |
| 17.1 Antiulcer medicines | | | | |
| <input type="checkbox"/> omeprazole | Solid oral dosage form: 10 mg, 20 mg Injection: 40 mg vial | B D | H | R |
| <input type="checkbox"/> ranitidine | Injection: 25 mg/ml (as hydrochloride) in 2 ml ampoule. Tablet: 150 mg (as hydrochloride) Oral liquid: 75 mg/5 ml (as | D B | H | R |

~ 23 ~



| | | | | |
|---|--|------------|----------|----------|
| | hydrochloride) | | | |
| 17.2 Antiemetic medicines | | | | |
| dexamethasone | Injection: 4 mg/ml in 1-ml ampoule (as disodium phosphate salt). Solid oral dosage form: 0.5 mg, 4 mg Oral liquid: 0.5 mg/5 ml | B A | | R |
| metoclopramide | Injection: 5 mg (hydrochloride/ml in 2-ml ampoule Tablet: 10 mg (hydrochloride). | A A | H | R |
| ondansetron [a] | Injection: 4 mg base/ml in 2-ml ampoule (as hydrochloride). Oral liquid: 4 mg base/5ml Solid oral dosage form: Eq 4 mg base; Eq 8 mg base; [a] >1 month. | D D | H | R |
| 17.3 Anti-inflammatory medicines | | | | |
| <input type="checkbox"/> sulfasalazine | Tablet: 500mg. | B | | R |
| <i>Complementary List</i> | | | | |
| prednisolone | Retention enema | D | H | R |
| 17.4 Laxatives | | | | |
| <input type="checkbox"/> senna | Tablet: 7.5 mg (sennosides)(or traditional dosage forms). | A | | R |
| 17.5 Medicines used in diarrhea | | | | |
| 17.5.1 Oral rehydration | | | | |
| oral rehydration salts | Powder for dilution in 200 ml;500 ml;1L. glucose: 75 mEq sodium: 75 mEq or mmol/L chloride: 65 mEq or mmol/L potassium: 20 mEq or mmol/L citrate: 10 mmol/L osmolarity: 245 mOsm/L glucose: 13.5 g/L sodium chloride: 2.6 g/L potassium chloride: 1.5 g/L trisodium citrate dihydrate+: 2.9 g/L + trisodium citrate dihydrate may be replaced by sodium hydrogen carbonate (sodium | A | | R |

~ 24 ~



| | | | | |
|---|---|----------|---|-----------|
| | bicarbonate) 2.5 g/L. However, as the stability of this latter formulation is very poor under tropical conditions, it is only recommended when manufactured for immediate use. | | | |
| 18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES | | | | |
| 18.1 Adrenal hormones and synthetic substitutes | | | | |
| fludrocortisone | Tablet: 100 micrograms (acetate). | D | | R |
| hydrocortisone | Tablet: 20 mg. | D | | R |
| 18.2 Androgens | | | | |
| <i>Complementary List</i> | | | | |
| testosterone | Injection: 250 mg (enanthate) in 1-ml ampoule. | D | H | R |
| 18.3 Contraceptives | | | | |
| 18.3.1 Oral hormonal contraceptives | | | | |
| ⊙ ethinylestradiol + ⊙ levonorgestrel | Tablet: 30 micrograms + 150 micrograms. | D | | R |
| Progestogen only oral contraceptive | Tablet: 0.075 mg | D | | - |
| 18.3.2 Injectable hormonal contraceptives | | | | |
| medroxyprogesterone acetate | Depot injection: 150 mg/ml in 1-ml vial. | D | | R |
| 18.3.3 Intrauterine devices | | | | |
| copper-containing device | | A | | R |
| 18.3.4 Barrier methods | | | | |
| condoms | | A | | Available |
| 18.4 Estrogens | | | | |
| conjugated Estrogens | Cream: 0.625 mg/gm | D | | R |
| 18.5 Insulins and other medicines used for diabetes | | | | |
| □ gliclazide* | Oral solid dosage form: (controlled release tablets) 60 mg; 80 mg. * Glimepiride 1mg, 2 mg, 3 mg, 4 mg | A | | R |
| glucagon | Injection: 1 mg/ml. | D | H | R |
| insulin injection (soluble) | Injection: 100 IU/ml in 10-ml vial. | D | | R |
| intermediate-acting insulin | Injection: 100 IU/ml in 10-ml vial (as compound insulin zinc suspension or isophane insulin), 3 ml cartridges | D | | R |
| metformin | Tablet: 500 mg, 850 mg, 1 g (hydrochloride). | A | | R |

~ 25 ~



| | | | | |
|--|--|---|---|----|
| 18.6 Ovulation inducers | | | | |
| <i>Complementary List</i> | | | | |
| clomifene | Tablet: 50 mg (citrate). | D | | R |
| 18.7 Progestogens | | | | |
| medroxyprogesterone acetate | Tablet: 5 mg | D | | R |
| progesterone | Cap/ovule: 100 mg | D | | R |
| norethisterone Acetate | Tablet: 5 mg | D | | R |
| 18.8 Thyroid hormones and antithyroid medicines | | | | |
| levothyroxine | Tablet: 25 micrograms [c]; 50 micrograms; 100 micrograms; 150 micrograms (sodium salt) | A | | R |
| carbimazole | Tablet: 5 mg | B | | |
| <i>Complementary List [c]</i> | | | | |
| lugol's solution | Oral liquid: about 130 mg total iodine/ml. | D | | |
| propylthiouracil | Tablet: 50 mg. | D | | |
| 18.9 Drugs Affecting Bone | | | | |
| 18.9.1 BIPHOSPHONATES | | | | |
| alendronic acids | Tablet: 70 mg | B | | R |
| 18.9.2 VITAMIN-D | | | | |
| alfacalcidol | Capsules: 0.25; 0.5 ; 1 micrograms Oral drops: 2 micrograms / 1 ml | B | | R |
| 18.10 Drugs for other endocrine disorders | | | | |
| 18.10.1 Somatostatins Analogues | | | | |
| octriotide | Injection: 0.1 mg / 1-ml | D | H | R |
| 18.10.2 Antidiuretic hormone analogues and antagonists | | | | |
| desmopressin | Nasal spray: 0.1 mg Tablets: 60 micrograms | D | | R |
| 18.10.3 Dopamine Agonists | | | | |
| cabergoline | Tablets: 0.5 mg | D | | R |
| 18.10.4 Androgens and ant-androgens | | | | |
| finasteride | | D | | R |
| 19. IMMUNOLOGICALS | | | | |
| 19.1 Diagnostic agents | | | | |
| All tuberculins should comply with the WHO Requirements for Tuberculins. | | | | |
| tuberculin, purified protein derivative (PPD) | Injection. | | | NR |
| 19.2 Sera and immunoglobulins | | | | |



| | | | | |
|--|---|--------|---|---|
| anti-D immunoglobulin (human) | Injection: 250 micrograms in single-dose vial, 300 micrograms | D | H | R |
| antirabies immunoglobulin (human) | Injection: 150 IU/ml in 2 ml vial | D | | R |
| antitetanus immunoglobulin (human) | Injection: 500 IU in 2ml vial | D | | R |
| antivenom immunoglobulin* | Injection. * Exact type to be defined locally. Anti-snake Anti-scopoin Stone fish | D D | | R |
| diphtheria antitoxin | Injection: 10 000 IU | D | | R |
| 19.3 Vaccines | | | | |
| Selection of vaccines from the Model List will need to be determined by each country after consideration of international recommendations, epidemiology and national priorities. | | | | |
| Tuberculosis, BCG vaccine | | A | | |
| poliomyelitis vaccine (OPV/IPV) | | A | | |
| Diphtheria & Tetanus, Pertussis DPT | | A | | |
| Haemophilus Influenza B, Hib | | A | | |
| Hepatitis B, HBV | | A | | |
| Measles | | A | | R |
| Measles, Mumps, Rubella MMR | | A | | |
| Rotavirus | | A | | R |
| 20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE INHIBITORS | | | | |
| <input type="checkbox"/> atracurium | Injection: 25 mg/ml(besylate) | D | H | R |
| neostigmine | Injection: 2.5 mg/ml, 0.5 mg/ampoule | D | H | R |
| suxamethonium | Injection: 50 mg (chloride)/ml in 2-ml ampoule | D | H | R |
| <input type="checkbox"/> vecuronium [c] | Powder for injection: 4 mg (bromide), | D | H | R |
| <i>Complementary List</i> | | | | |
| pyridostigmine | Tablet: 60 mg (bromide). | | | R |
| <input type="checkbox"/> vecuronium [c] | Powder for injection: 4 mg (bromide), | D | H | R |
| 21. OPHTHALMOLOGICAL PREPARATIONS | | | | |
| 21.1 Anti-infective agents | | | | |



| | | | | |
|--|---|---|---|----------|
| acyclovir | Ointment: 3% W/W. | B | | R |
| azithromycin | Solution (eye drops): 1.5%. | B | | R |
| ⊗ gentamicin | Solution (eye drops): 0.3% (sulfate). | A | | R |
| ⊗ ofloxacin | Solution (eye drops): 0.3%. | B | | R |
| ⊗ tetracycline | Eye ointment: 1% (hydrochloride). | B | | R |
| ciprofloxacin | Solution: 0.3% | B | | R |
| 21.2 Anti-inflammatory agents | | | | |
| ⊗ prednisolone | Solution (eye drops): 0.5% (sodium phosphate). | B يصرف للمراكز الصحية التي يتوافر بها اخصائي عيون | | R |
| 21.3 Local anaesthetics | | | | |
| ⊗ tetracaine a | Solution (eye drops): 0.5% (hydrochloride). a Not in preterm neonates. | B | | R |
| 21.4 Miotics and antiglaucoma medicines | | | | |
| acetazolamide | Tablet: 250 mg. | B | | R |
| latanoprost | Solution (eye drops): latanoprost 50 micrograms/mL | D | | R |
| ⊗ pilocarpine | Solution (eye drops): 2%; 4% (hydrochloride or nitrate). | B | | R |
| ⊗ timolol | Solution (eye drops): 0.25%; 0.5% (as hydrogen maleate). | D | | R |
| 21.5 Mydriatics | | | | |
| atropine* a | Solution (eye drops): 0.1%; 0.5%; 1% (sulfate). * [c] Or homatropine (hydrobromide) or cyclopentolate (hydrochloride). a >3 months. | B يصرف للمراكز الصحية التي يتوافر بها اخصائي عيون | | R |
| 21.6 Anti vascular endothelial growth factor (VEGF) | | | | |
| <i>Complementary List</i> | | | | |
| bevacizumab | Injection: 100 mg/ml. | D | H | R |
| 22. OXYTOCICS AND ANTIOXYTOCICS | | | | |
| 22.1 Oxytocics | | | | |
| ⊗ ergometrine | Injection: 200 micrograms (hydrogen maleate) in 1-ml ampoule. | D | H | R |
| misoprostol | Tablet: 200 micrograms.* * For management of incomplete | D | H | R |

~ 28 ~



| | | | | |
|--|--|---|---|---|
| | abortion and miscarriage, and for prevention of postpartum haemorrhage where oxytocin is not available or cannot be safely used. * Only for use for induction of labour where appropriate facilities are available. | | | |
| oxytocin | Injection: 10 IU in 1-ml. | D | H | R |
| 23. PERITONEAL DIALYSIS SOLUTION | | | | |
| <i>Complementary List</i> | | | | |
| Intra-peritoneal dialysis solution(of appropriate composition) | | D | H | R |
| 24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS | | | | |
| 24.1 Medicines used in psychotic disorders | | | | |
| ⊗ haloperidol | Injection: 5 mg in 1-ml ampoule. Oral liquid: 2 mg/ml. Solid oral dosage form: 5 mg, 10 mg | C1 | H | R |
| risperidone | Oral solid dosage form: 1, 4 mg | C1 | | R |
| <i>Complementary List</i> | | | | |
| ⊗ haloperidol | Injection: 5 mg in 1-ml ampoule. Oral liquid: 2 mg/ml. Solid oral dosage form: 5 mg, 10 mg | C1 | H | R |
| 24.2 Medicines used in mood disorders | | | | |
| 24.2.1 Medicines used in depressive disorders | | | | |
| ⊗ amitriptyline | Tablet: 25 mg; | | | R |
| fluoxetine | Solid oral dosage form: 20 mg (as hydrochloride). a >8 years. | B يصرّف من قبل الاطباء الحاصلين على موافقة الوزير لبرنامج سد الفجوة النفسية | | R |
| <i>Complementary List</i> | | | | |
| fluoxetine a | Solid oral dosage form: 20 mg (as hydrochloride). a >8 years. | B يصرّف من قبل الاطباء الحاصلين على موافقة الوزير | | R |

~ 29 ~

A مراكز اولية:
B مراكز شاملة:
C مراكز متخصصة:
C1 عيادات نفسية:
D مستشفيات:

الرمز H يعني استخدامه داخل المستشفى

ادوية تم اضافتها



| | | لبرنامج سد الفجوة النفسية | | |
|---|--|----------------------------------|---|---|
| 24.2.2 Medicines used in bipolar disorders | | | | |
| lithium carbonate | Solid oral dosage form: 250, 400 mg | C1 يصرف من قبل أخصائي نفسي | | R |
| valproic acid (sodium valproate) | Oral liquid: 200 mg/1 ml, 300 mg/1 ml Tablet (enteric-coated): 150 mg; 500 mg (sodium valproate). | B C1 | | R |
| 24.3 Medicines for anxiety disorders | | | | |
| <input type="checkbox"/> diazepam | Injection: 5 mg/ml. Tablet: 5 mg; 10 mg. | A A | H | R |
| 24.4 Medicines used for obsessive compulsive disorders | | | | |
| clomipramine | Tab. 25, 10, mg | B | | R |
| 24.5 Medicines for disorders due to psychoactive substance use | | | | |
| methylphenidate | Tab: 10 mg | D | | R |
| <i>Complementary List</i> | | | | |
| <input type="checkbox"/> methadone* | Oral liquid: 2 mg/ml | D | | R |
| 25. MEDICINES ACTING ON THE RESPIRATORY TRACT | | | | |
| 25.1 Antiasthmatic and medicines for chronic obstructive pulmonary disease | | | | |
| <input type="checkbox"/> beclometasone | Inhalation (aerosol): 50 micrograms (dipropionate) per dose; 250 micrograms (dipropionate) per dose (as CFC free forms). | B | | R |
| <input type="checkbox"/> budesonide [c] | Inhalation (aerosol): 200 micrograms per dose. | B | | R |
| epinephrine (adrenaline) | Injection: 1 mg (as hydrochloride or hydrogen tartrate) in 1-ml ampoule. | A | H | R |
| ipratropium bromide | Inhalation (aerosol): 20 micrograms/metered dose. Vial: 250 micrograms/vial | B | | R |
| formoterol | Inhalation: 12 micrograms inhaler, 4.5 micrograms turbuhaler, 9 micrograms turbuhaler | B | | R |
| <input type="checkbox"/> salbutamol | Inhalation (aerosol): 100 micrograms (as sulfate) per dose. Injection: 50 micrograms (as sulfate)/ml in 5-ml ampoule. | A | | R |

~ 30 ~

A مراكز أولية:
B مراكز شاملة:
C مراكز متخصصة:
C1 عيادات نفسية:
D مستشفيات:

الرمز H يعني استخدامه داخل المستشفى

ادوية تم اضافتها



| | | | | |
|---|---|---|---|---|
| | Metered dose inhaler (aerosol): 100 micrograms (assulfate) per dose. | | | |
| 26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES | | | | |
| 26.1 Oral | | | | |
| oral rehydration salts | See section 17.5.1. | | | R |
| 26.2 Parenteral | | | | |
| glucose | Injectable solution: 5% (isotonic); 10% (hypertonic); 25% (hypertonic); 50% (hypertonic). | | | R |
| glucose with sodium chloride | Injectable solution: 4% glucose, 0.18% sodium chloride (equivalent to Na ⁺ 30 mmol/L, Cl ⁻ 30 mmol/L). Injectable solution: 5% glucose, 0.9% sodium chloride (equivalent to 150 mmol/L Na ⁺ and 150 mmol/L Cl ⁻); 5% glucose, 0.45% sodium chloride (equivalent to 75 mmol/L Na ⁺ and 75 mmol/L Cl ⁻) [c]. | | | R |
| potassium chloride | Solution: 11.2% in 20-ml ampoule (equivalent to K ⁺ 1.5 mmol/ml, Cl ⁻ 1.5 mmol/ml). Solution for dilution: 7.5% (equivalent to K ⁺ 1 mmol/ml and Cl ⁻ 1 mmol/ml) [c]; 15% (equivalent to K ⁺ 2 mmol/ml and Cl ⁻ 2 mmol/ml) [c]. | D | H | R |
| sodium chloride | Injectable solution: 0.9% isotonic (equivalent to Na ⁺ 154 mmol/L, Cl ⁻ 154 mmol/L). | D | H | R |
| sodium hydrogen carbonate | Injectable solution: 1.4% isotonic (equivalent to Na ⁺ 167 mmol/L, HCO ₃ ⁻ -167 mmol/L). Solution: 8.4% in 10-ml ampoule (equivalent to Na ⁺ 1000 mmol/L, HCO ₃ ⁻ -1000 mmol/L). | D | H | R |
| <input type="checkbox"/> sodium lactate, compound solution | Injectable solution. | D | H | R |
| 26.3 Miscellaneous | | | | |
| water for injection | 2-ml; 5-ml; 10-ml ampoules. | D | | R |
| 27. VITAMINS AND MINERALS | | | | |
| ascorbic acid | Tablet: 50 mg. | A | | R |



| | | | | |
|---|--|---|---|---|
| calcium | Tablet: 500 mg (elemental). | A | | R |
| <input type="checkbox"/> nicotinamide | Tablet: 50 mg. | A | | R |
| pyridoxine | Tablet: 25 mg (hydrochloride). | A | | R |
| retinol | Capsule: 50 000 IU; 100 000 IU; 200 000 IU (as palmitate). Oral oily solution: 100 000 IU (as palmitate)/ml in multidose dispenser. Tablet (sugar-coated): 10 000 IU (as palmitate). Water-miscible injection: 100 000 IU (as palmitate) In 2-ml ampoule. | | | R |
| riboflavin | Tablet: 5 mg. | A | | R |
| thiamine | Tablet: 50 mg (hydrochloride). | A | | R |
| <i>Complementary List</i> | | | | |
| calcium gluconate | Injection: 100 mg/ml in 10-ml ampoule. | D | | R |
| 28. EAR, NOSE AND THROAT MEDICINES IN CHILDREN [c] | | | | |
| acetic acid | Topical: 2%, in alcohol. | A | | |
| <input type="checkbox"/> budesonide | Nasal spray: 64 micrograms per dose. | B | | R |
| <input type="checkbox"/> ciprofloxacin | Topical: 0.3% drops (as hydrochloride). | B | | R |
| <input type="checkbox"/> xylometazoline * | Nasal spray: 0.05%. * Not in children less than 3 months. | B | | R |
| 29. SPECIFIC MEDICINES FOR NEONATAL CARE | | | | |
| 29.1 Medicines administered to the neonate [c] | | | | |
| chlorhexidine | Solution or gel: 7.1% (digluconate) delivering 4%chlorhexidine (for umbilical cord care) [c]. | D | H | R |
| <i>Complementary List</i> | | | | |
| <input type="checkbox"/> prostaglandin E | Solution for injection: Prostaglandin E1: 0.5 mg/ml in alcohol. Prostaglandin E 2: 1 mg/ml. | D | H | R |
| surfactant | Suspension for intratracheal instillation: 25 mg/ml or 80 mg/ml. (checking with INN – Secretariat) | D | H | R |
| 29.2 Medicines administered to the mother | | | | |
| dexamethasone | Injection: 4 mg/ml dexamethasone phosphate (as disodium salt) | D | H | R |



| 30. MEDICINES FOR DISEASES OF JOINTS | | | | |
|---|--|---|--|---|
| 30.1 Medicines used to treat gout | | | | |
| allopurinol | Tablet: 100mg, 300mg * Colchicine 1mg. | A | | R |
| 30.2 Disease modifying agents used in rheumatoid disorders (DMARDs) | | | | |
| chloroquine | Tablet: 100 mg; 150 mg (as phosphate or sulfate). | C | | R |
| <i>Complementary List</i> | | | | |
| azathioprine | Tablet: 50 mg. | D | | R |
| hydroxychloroquine [c] | Solid oral dosage form: 200 mg (as sulfate). | | | R |
| methotrexate | Tablet: 2.5 mg (as sodium salt) | D | | R |
| penicillamine | Solid oral dosage form: 250 mg. | D | | R |
| sulfasalazine | Tablet: 500 mg. | B | | R |
| 30.3 Juvenile joint diseases | | | | |
| acetylsalicylic acid* (acute or chronic use) | Suppository: 50 mg to 150 mg. Tablet: 100 mg to 500 mg. * For use for rheumatic fever, juvenile arthritis, Kawasaki disease. | A | | R |

